1. P1054: MYLOX-1: AN OPEN-LABEL, PHASE IIA STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR, GB2064, IN MYELOFIBROSIS. (23rd June 2022) Authors: Harrison, C.; Mascarenhas, J.; Rampal, R.; Cilloni, D.; Lindmark, B.; Singh, B.; Jacoby, B.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 944 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗